Primary liver / biliary tract cancer: clinical trials in Switzerland
11 open trials in Switzerland for primary liver / biliary tract cancer and 17 open trials accepting several types of cancer, according to ClinicalTrials.gov, updated on October 20, 2026.
These results are indicative and do not replace medical advice — discuss them with your doctor.
Open trials
- A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
NCT06428409RecruitingPhase 1 · Phase 2
In Switzerland: Bellinzona, Geneva
- Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
NCT05176483RecruitingPhase 1
In Switzerland: St. Gallen, Winterthur
- DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.
NCT07717437Recruiting
In Switzerland: Zurich
- FAPI PET Imaging - An Exploratory Study
NCT07705074Not yet recruitingPhase 1 · Phase 2
In Switzerland: Baden, Geneva, Genolier, Lucerne, Zurich
- Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer
NCT06274879RecruitingPhase 2
In Switzerland: Bern, Geneva, Lucerne, Zurich
- Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resection
NCT07461675Not yet recruitingPhase 3
In Switzerland: Geneva
- Transarterial Chemoembolization (TACE) Plus ABCB1 Inhibition Versus TACE Alone in Patients With Hepatocellular Carcinoma
NCT07302919RecruitingPhase 2 · Phase 3
In Switzerland: Basel, Geneva, St. Gallen
- HOPE Against Cancer Recurrence in HCC
NCT06717919RecruitingPhase 4
In Switzerland: Basel, Geneva, Zurich
- The Dragon PLC Trial (DRAGON-PLC)
NCT06914648Recruiting
In Switzerland: Basel, Lausanne, Lucerne, Winterthur, Zurich
- Improving Hepatocellular Carcinoma Screening
NCT05828446Recruiting
In Switzerland: Lausanne
- The European NAFLD Registry
NCT04442334Recruiting
In Switzerland: Bern
Trials open to several types of cancer
These trials accept several types of cancer, perhaps yours: talk to your doctor about them.
- A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010)
NCT07785609RecruitingPhase 2
In Switzerland: Bellinzona, St. Gallen
- A Beta-only IL-2 ImmunoTherapY Study
NCT05086692RecruitingPhase 1 · Phase 2
In Switzerland: Zurich
- A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002)
NCT07793942Not yet recruitingPhase 2
In Switzerland: Lausanne, St. Gallen
- A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
NCT05067283RecruitingPhase 1
In Switzerland: Bellinzona, St. Gallen
- Anti-GD2 ADC M3554 in Advanced Solid Tumors
NCT06641908RecruitingPhase 1
In Switzerland: Zurich
- A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06760819RecruitingPhase 2
In Switzerland: Bern, Geneva, Zurich
- Safety and Early Signs of Efficacy of IL12-L19L19.
NCT04471987RecruitingPhase 1
In Switzerland: Basel, Bellinzona, Bern, Geneva
- A Nutrition and Exercise Program With Olanzapine Compared to Olanzapine Alone: A Trial in Patients With Advanced Tumors
NCT07722806Not yet recruitingPhase 2
In Switzerland: Winterthur
- A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
NCT05836324RecruitingPhase 1
In Switzerland: Bellinzona, Lausanne, St. Gallen
- A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation
NCT07172919RecruitingPhase 2
In Switzerland: Basel
- A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
NCT05384626RecruitingPhase 1 · Phase 2
In Switzerland: Bellinzona, Lucerne
- A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours
NCT06725758RecruitingPhase 1 · Phase 2
In Switzerland: Bellinzona
- First in Human Study of T3P-Y058-739 (T3P)
NCT05120596RecruitingPhase 1 · Phase 2
In Switzerland: Bern, Lausanne, Zurich
- Tumor Molecular Profiling in Early Phase Clinical Trials
NCT04510766Recruiting
In Switzerland: Bellinzona
- A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
NCT04775485RecruitingPhase 2
In Switzerland: Zurich
- Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors
NCT06408688RecruitingPhase 4
In Switzerland: Baden, Basel, Liestal, St. Gallen
- INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies
NCT03838042RecruitingPhase 1 · Phase 2
In Switzerland: Zurich